New Heart Failure Treatment Protocol Reduces Mortality by Nearly Two-Thirds in UK Hospitals
• A new "rapid titration" protocol for heart failure treatment being implemented in UK hospitals cuts mortality by 62% and reduces rehospitalization by 30% compared to traditional approaches.
• St George's Hospital in London and Morriston Hospital in Swansea are the first UK centers to adopt this protocol, which achieves optimal medication dosing within 2-3 weeks instead of the traditional 9-12 months.
• The approach, validated through the multinational STRONG-HF trial involving 87 hospitals across 14 countries, represents a significant advancement in treating the incurable condition affecting one million Britons.
BHF PROTECT-TAVI Trial Fails to Show Benefit of Cerebral Embolic Protection During TAVI
• The large-scale BHF PROTECT-TAVI trial found no reduction in stroke risk with routine cerebral embolic protection during transcatheter aortic valve implantation, confirming similar results from the earlier PROTECTED TAVR trial.
• Despite the device's ability to capture dislodged emboli during procedures, researchers found no clinical benefit across any patient subgroups, challenging the intuitive assumption that debris capture would translate to improved outcomes.
• Following these negative findings, experts predict further decline in embolic protection device usage, which had already decreased from 13.5% to 10.2% in US hospitals after the PROTECTED TAVR results were published.
Novel Minimally Invasive 'Triple T' Therapy Shows Promise in Treating Primary Aldosteronism
• UK researchers have developed Triple T (Targeted Thermal Therapy), a groundbreaking 20-minute minimally invasive procedure that treats primary aldosteronism without removing the adrenal gland.
• The FABULAS trial demonstrated Triple T's safety and effectiveness in 28 patients, with most achieving normal hormone levels after six months and many discontinuing blood pressure medications.
• This innovative treatment could potentially help millions worldwide, as primary aldosteronism affects 1 in 20 people with high blood pressure but is currently underdiagnosed and undertreated.
ACC.25 Highlights Novel Therapies and Strategies in Cardiovascular Care
• The SOUL trial demonstrated that oral semaglutide significantly reduces cardiovascular events in type 2 diabetes patients with atherosclerotic cardiovascular and/or chronic kidney disease.
• The RIVAWAR trial investigated the efficacy of rivaroxaban versus warfarin in patients with acute left ventricular thrombus following myocardial infarction.
• The FAIR-HF2 trial assessed the impact of ferric carboxymaltose on morbidity and mortality in patients with iron deficiency and chronic heart failure.
• The ALPACA Phase 2 trial of Lepodisiran showed promising results for an extended duration small-interfering RNA targeting Lipoprotein(a).
Revolutionary Heart Valve That Grows Inside the Body to be Tested in UK
A groundbreaking development in regenerative medicine, a heart valve that grows inside the body, is set to be tested on British cardiac patients. This innovation, led by Professor Sir Magdi Yacoub, promises a significant advancement for treating congenital heart defects in children, as the valve grows with the patient, eliminating the need for repeated surgeries.
AI Model Predicts High Blood Pressure and Complications from ECGs
A new AI model developed by researchers at Imperial College London can predict the risk of high blood pressure and related complications using electrocardiogram (ECG) data. This technology, set for clinical trials with NHS patients, aims to enable earlier intervention and lifestyle changes to prevent hypertension and its serious consequences.
NHS Trials AI System 'Aire-DM' for Early Type 2 Diabetes Detection
• Two NHS hospital trusts in London are trialing an AI system, Aire-DM, to detect early warning signs of type 2 diabetes using ECG heart traces.
• Early data suggests Aire-DM can predict diabetes risk with approximately 70% accuracy, which improves when combined with patient data like age and blood pressure.
• The AI analyzes subtle ECG changes undetectable by doctors, potentially identifying at-risk individuals up to a decade before the onset of the condition.
• Clinical trials are planned for 2025, and if successful, the technology could be widely implemented within the NHS in five or more years, aiding in early intervention and prevention.
FDA Approves Journavx, a Novel Non-Opioid Painkiller, Offering New Hope for Acute Pain Management
• The FDA has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic, for treating moderate to severe acute pain in adults, offering a safer alternative to opioids.
• Journavx works by selectively blocking pain signals in the peripheral nervous system, reducing pain without the addictive potential and severe side effects associated with opioids.
• Clinical trials demonstrated Journavx's effectiveness in reducing pain after surgeries, with a safety profile comparable to placebo, though it didn't outperform opioid-acetaminophen combinations.
• Priced at $15.50 per pill, Journavx faces challenges in accessibility due to its higher cost compared to generic opioids, but it represents a significant step in combating the opioid crisis.
Early Aortic Valve Intervention Fails to Show Benefit in Asymptomatic Patients with Severe Aortic Stenosis and Myocardial Fibrosis
• A randomized clinical trial involving 224 patients revealed that early aortic valve intervention did not significantly reduce the composite outcome of all-cause death or unplanned aortic stenosis-related hospitalization.
• The study focused on asymptomatic patients with severe aortic stenosis who also exhibited myocardial fibrosis, a condition associated with adverse long-term prognosis.
• Early intervention was associated with a lower rate of NYHA class II-IV symptoms at 12 months, suggesting a potential benefit in symptom management.
• Further research is needed to confirm these findings, as the trial had a wide confidence interval around the primary endpoint.
Gender Gap in Heart Disease: Women Face Higher Misdiagnosis Risks and Mortality Rates
• British Heart Foundation research reveals women are 50% more likely to receive misdiagnosis during cardiac episodes, with misdiagnosed patients facing 70% higher mortality risk.
• Risk factors like smoking, high blood pressure, and type 2 diabetes pose significantly greater heart attack risks for women compared to men, with smoking doubling the risk specifically for women.
• UK projections show 550,000 diagnosed cases of coronary artery disease in women by 2024, highlighting the urgent need to address gender disparities in cardiac care.
Torasemide Shows Promise in Genetically-Targeted Hypertension Treatment
• A new study reveals that torasemide, a loop diuretic, significantly reduces blood pressure in hypertension patients with a specific UMOD gene variant.
• Patients with two copies of the UMOD gene variation experienced a 5% reduction in average blood pressure after 16 weeks of torasemide treatment.
• The research suggests personalized treatment based on genetic profiles could improve hypertension management, especially for those with uncontrolled blood pressure.
• Larger trials are needed to confirm torasemide's efficacy as a tool against uncontrolled hypertension, potentially benefiting millions.
Vutrisiran Shows Promise in Reducing Hospitalization and Deaths in ATTR Cardiac Amyloidosis
• A new study reveals that vutrisiran, a gene-silencing drug, significantly reduces the risk of death and cardiovascular events in patients with transthyretin (ATTR) cardiac amyloidosis.
• The HELIOS-B clinical trial demonstrated a 28% reduction in the risk of death and recurring cardiovascular events over three and a half years with vutrisiran treatment.
• Vutrisiran, which blocks the production of the disease-causing TTR protein, improved the quality of life and showed benefits in disease progression markers among treated patients.
• The findings suggest vutrisiran could become a new standard of care for ATTR cardiac amyloidosis, offering a significant advancement in treating this progressive and often fatal disease.
Wegovy Approved in the UK to Prevent Heart Attacks and Strokes in Overweight Individuals
• Semaglutide (Wegovy) has been approved in the UK to reduce the risk of heart attacks and strokes in overweight or obese individuals with established cardiovascular disease.
• The approval by the Medicines and Healthcare products Regulatory Agency (MHRA) marks the first weight-loss drug authorized for cardiovascular disease prevention in the UK.
• Clinical trial data showed Wegovy significantly reduced the risk of major adverse cardiovascular events by 20% in a study of over 17,600 participants.
• The drug, which mimics the GLP-1 hormone to suppress appetite, will be available to individuals with a BMI of 27 or higher who have existing heart conditions.
© Copyright 2025. All Rights Reserved by MedPath